Spironolactone for Hirsutism in Polycystic Ovary Syndrome

@article{Christy2005SpironolactoneFH,
  title={Spironolactone for Hirsutism in Polycystic Ovary Syndrome},
  author={Natalie A Christy and Andrea S. Franks and L. Brian Cross},
  journal={Annals of Pharmacotherapy},
  year={2005},
  volume={39},
  pages={1517 - 1521}
}
OBJECTIVE: To evaluate the level of evidence for treatment of hirsutism associated with polycystic ovary syndrome (PCOS) with spironolactone. DATA SOURCES: Studies and reports were located in MEDLINE (1966–January 2005%), EMBASE, and International Pharmaceutical Abstracts through the second week of January 2005. DATA SYNTHESIS: Hirsutism is a common clinical problem and is often associated with PCOS. Research has been performed to assess the efficacy of spironolactone therapy in patients with… Expand
Polycystic ovary syndrome: a review for dermatologists: Part II. Treatment.
TLDR
Treatment recommendations are made based on the current available evidence regarding treatments for women with acne, hirsutism, and androgenetic alopecia. Expand
Polycystic ovary syndrome: a review for dermatologists: Part I. Diagnosis and manifestations.
TLDR
The definition, etiology, pathogenesis, and clinical features of PCOS are reviewed, including the hallmark features of hyperandrogenism and hyperinsulinemia. Expand
Update on the management of polycystic ovary syndrome.
TLDR
The management of PCOS is complex and includes lifestyle modification combined with dietary-induced weight loss, oral contraceptives, clomiphene citrate, gonadotropins, antiandrogens and insulin-sensitizing agents, which describes all these treatment options. Expand
Diagnosis and Management of Polycystic Ovary Syndrome in Adolescent Girls.
TLDR
Lifestyle modification is the cornerstone of treatment for girls with PCOS; however, hormonal medication such as oral contraceptive pills and insulin-sensitizing agents are useful and effective adjuncts to therapy. Expand
What therapies alleviate symptoms of polycystic ovary syndrome
TLDR
Treatment of polycystic ovary syndrome in women not actively seeking to become pregnant is symptom-specific and treatment with metformin or spironolactone may be better tolerated. Expand
Treatment strategies for women with polycystic ovary syndrome
  • Peipei Jin, Yongyong Xie
  • Medicine
  • Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2018
TLDR
Because current treatments cannot cure PCOS, lifelong administration is still the mainstream method of management; however, the optimal treatment plan needs further research and exploration. Expand
Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss.
TLDR
Satisfactory treatment response to antiandrogen therapy supports the involvement of androgens in the pathogenesis of female pattern hair loss and spironolactone has been used off-label in FPHL for over 20 years. Expand
Comprehensive clinical management of hirsutism
TLDR
A general overview of hirsutism treatment options is presented, which includes laser hair removal, electrolysis, depilatory creams, plucking and waxing. Expand
MEHANIZMI SRČNO-ŽILNE OGROŽENOSTI ŽENSK S SINDROMOM POLICISTIČNIH OVARIJEV MECHANISMS OF CARDIOVASCULAR DISEASE RISKS IN WOMEN WITH POLYCYSTIC OVARY SYNDROME
TLDR
Reciprocal relationships between endothelial dysfunction, early pre-clinical form of atherosclerosis, and insulin resistance, key metabolic disturbance in PCOS, mark the pathogenesis of Atherosclerosis inPCOS. Expand
Diagnosis and treatments of hirsutism: where are we?
TLDR
Hirsutism refers to an excess of terminal hair on body sites where terminal hair is normally minimal or absent, and may be idiopathic or secondary to virilization, in which case it may be a sign of a serious medical condition. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 22 REFERENCES
Therapeutic Effects of Spironolactone in Polycystic Ovary Syndrome
TLDR
In all patients a significant decrease in hirsutism was noted as well as restoration of a regular although anovulatory menstrual pattern after three months of spironolactone treatment, and this therapy is recommended as initial nontoxic but effective treatment for women with polycystic ovary syndrome. Expand
Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study.
TLDR
The ethinyl estradiol/DRSP combination seems to be effective in ameliorating clinical and hormonal features of PCOS. Expand
A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.
TLDR
Polycystic ovary syndrome appears to be a particularly common endocrine disorder in the Greek population under study and it is associated with certain metabolic abnormalities, suggesting that the severity of the fasting hyperinsulinemia isassociated with the severity with the clinical phenotype of hyperandrogenism independently of obesity. Expand
Current concepts in the polycystic ovary syndrome.
TLDR
Increased androgen secretion and insulin resistance persist in cultured theca cells and skin fibroblasts from women with PCOS; this finding suggests that these are intrinsic, presumably genetic, defects. Expand
A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain.
TLDR
A 6.5% prevalence of PCOS is demonstrated in a minimally biased population of Caucasian women from Spain, in a population of 154 Caucasian women of reproductive age reporting spontaneously for blood donation. Expand
Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study.
TLDR
Both drugs are effective in the management of PCOS and spironolactone appears better than metformin in the treatment of hirsutism, menstrual cycle frequency, and hormonal derangement and is associated with fewer adverse events. Expand
A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women.
TLDR
Finasteride and spironolactone treatment resulted in a similar clinical effect on hirsutism, and further studies with finasteride are needed to verify its effectiveness as a treatment for hirsUTism. Expand
Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study.
TLDR
In a consecutive population of unselected women the prevalence of hirsutism varied from 2-8% depending on the chosen cut-off F-G score, with no significant difference between White and Black women. Expand
Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial.
TLDR
After a 6-month course of therapy, the clinical efficacies of these drugs, at least at the doses used, are similar and are all effective in the treatment of hirsutism. Expand
Spironolactone as a single agent for long‐term therapy of hirsute patients
To assess the androgen‐suppressing effect of spironolactone, and the use of this drug as a single agent in the long‐term therapy of hirsute patients with either polycystic ovary syndrome (PCOS) orExpand
...
1
2
3
...